SCHEMBL6088056

SCHEMBL6088056

O=C1Nc2ccc(Cl)cc2C1=C1OCc2cc(NCCN3CCOCC3)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.44
FLT3 P36888 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
PAK1 Q13153 2/20 0.43
MAPK14 Q16539 2/20 0.42
PDGFRB P09619 3/20 0.41
KDR P35968 3/20 0.41
KIT P10721 2/20 0.41
CNR1 P21554 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.38
APAF1 O14727 1/20 0.38
NSD2 O96028 1/20 0.38
KMT2A Q03164 1/20 0.38
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6088052 1.00 LRRK2 (0.44) LRRK2FLT3PSEN1PSEN2APH1B
SCHEMBL6087048 0.91 MAPK14 (0.50) LRRK2FLT3PAK1MAPK14PDGFRB
SCHEMBL6087052 0.91 MAPK14 (0.50) LRRK2FLT3PAK1MAPK14PDGFRB
SCHEMBL6086453 0.89 MAPK14 (0.44) LRRK2MAPK14PDGFRBKDRKIT
SCHEMBL6086446 0.89 MAPK14 (0.44) LRRK2MAPK14PDGFRBKDRKIT
SCHEMBL6087057 0.86 MAPK14 (0.51) LRRK2MAPK14PDGFRBKDRKIT
SCHEMBL6087065 0.86 MAPK14 (0.51) LRRK2MAPK14PDGFRBKDRKIT
SCHEMBL6633573 0.86 PDGFRB (0.50) LRRK2FLT3MAPK14PDGFRBKDR
SCHEMBL6633575 0.86 PDGFRB (0.50) LRRK2FLT3MAPK14PDGFRBKDR
SCHEMBL6087877 0.84 ALDH1A1 (0.48) PAK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 545/4885FLT3 298/4885PSEN1 3304/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 LRRK2 497/4885FLT3 312/4885PSEN1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.